Preprint Review Version 2 Preserved in Portico This version is not peer-reviewed

Unveiling a Biomarker Signature of Meningioma: the Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis

Reem Halabi
,
Fatima Dakroub
,
Mohammad Z. Haider
ORCID logo ,
Stuti Patel
,
Nayef A. Amhaz
,
Mohammad A. Reslan
,
Ali H. Eid
ORCID logo ,
Yehia Mechref
ORCID logo ,
Nadine Darwiche
ORCID logo ,
Firas H. Kobeissy
ORCID logo ,
Ibrahim Omeis
* ,
Abdullah Shaito
*
Version 1 : Received: 16 August 2023 / Approved: 16 August 2023 / Online: 17 August 2023 (09:34:37 CEST)
Version 2 : Received: 3 November 2023 / Approved: 3 November 2023 / Online: 3 November 2023 (16:28:48 CET)

A peer-reviewed article of this Preprint also exists.

Halabi, R.; Dakroub, F.; Haider, M.Z.; Patel, S.; Amhaz, N.A.; Reslan, M.A.; Eid, A.H.; Mechref, Y.; Darwiche, N.; Kobeissy, F.; Omeis, I.; Shaito, A.A. Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis. Cancers 2023, 15, 5339. Halabi, R.; Dakroub, F.; Haider, M.Z.; Patel, S.; Amhaz, N.A.; Reslan, M.A.; Eid, A.H.; Mechref, Y.; Darwiche, N.; Kobeissy, F.; Omeis, I.; Shaito, A.A. Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis. Cancers 2023, 15, 5339.

Abstract

Meningiomas are the most prevalent primary intracranial tumors. The majority are benign but can undergo dedifferentiation into advanced grades classified by World Health Organization (WHO) into Grades 1 to 3. Meningiomas tremendous variability in tumor behavior and slow growth rates complicate their diagnosis and treatment. A deeper comprehension of the molecular pathways and cellular microenvironment factors implicated in meningioma survival and pathology is needed. This review summarizes the known genetic and epigenetic aberrations involved in meningioma, with a focus on Neurofibromatosis type 2 (NF2) and non-NF2 mutations. Novel potential biomarkers for meningioma diagnosis and prognosis are also discussed, including epigenetic-, RNA-, metabolomics, and protein-based markers. Finally, the landscape of available meningioma-specific animal models is overviewed. Use of these animal models can enable planning of adjuvant treatment, potentially assisting in preoperative and postoperative decision-making. Discovery of novel biomarkers will allow, in combination with WHO grading, more precise meningioma grading, including meningioma identification, subtype determination, and prediction of metastasis, recurrence, and response to therapy. Moreover, these biomarkers may be exploited in the development of personalized targeted therapies that can distinguish between the 15 diverse meningioma subtypes.

Keywords

Meningioma; NF2 mutations; biomarker; miRNA; proteomics

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (1)

Comment 1
Received: 3 November 2023
Commenter: Abdullah Shaito
Commenter's Conflict of Interests: Author
Comment: Modifications during review process.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.